Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy

International Journal of Cancer

Volumn 134, Issue 11, 2014, Pages 2572-2582

  Raykov, Zahary ^a,b   Grekova, Svitlana P ^a,b   Bour, Gaétan ^a,b   Lehn, Jean Marie ^c   Giese, N A ^d   Nicolau, Claude ^e,f   Aprahamian, Marc ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Cancer Virotherapy Unit   (Germany)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e NormOxys Inc   (United States)

^f TUFTS UNIVERSITY   (United States)

Author keywords

ITPP; normoxia; pancreatic cancer

Indexed keywords

GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INOSITOL TRISPHOSPHATE; NITRIC OXIDE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INFILTRATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FLUORESCENCE ACTIVATED CELL SORTING; FLUOROMETRY; HISTOPATHOLOGY; HYPOXIA; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MALE; METASTASIS INHIBITION; NONHUMAN; OXYGEN TENSION; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ITPP; NORMOXIA; PANCREATIC CANCER;

ANIMALS; ANOXIA; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG SYNERGISM; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INOSITOL PHOSPHATES; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; PANCREATIC NEOPLASMS; RATS; RATS, INBRED LEW; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84896393449     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28597     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Ghaneh P, Smith R, Tudor-Smith C, et al. Neoadjuvant and adjuvant strategies for pancreatic cancer. Eur J Surg Oncol 2008; 34: 297-305.
3. Bachem MG, Schunemann M, Ramadani M, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 2005; 128: 907-21.
4. Koong AC, Mehta VK, Le QT, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000; 48: 919-22.
5. Semenza GL,. Life with oxygen. Science 2007; 318: 62-4.
6. Akakura N, Kobayashi M, Horiuchi I, et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001; 61: 6548-54.
7. Baluk P, Morikawa S, Haskell A, et al. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003; 163: 1801-15.
8. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
9. Rausch V, Liu L, Apel A, et al. Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment. J Pathol 2012; 227: 325-35.
10. Kizaka-Kondoh S, Itasaka S, Zeng L, et al. Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res 2009; 15: 3433-41.
11. Schwartz DL, Bankson JA, Lemos R, Jr,., et al. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 2010; 9: 2057-67.
12. Aprahamian M, Bour G, Akladios CY, et al. Myo-InositolTrisPyroPhosphate treatment leads to HIF-1alpha suppression and eradication of early hepatoma tumors in rats. Chembiochem 2011; 12: 777-83.
13. Kieda C, Greferath R, Crola da Silva C, et al. Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes. Proc Natl Acad Sci U S A 2006; 103: 15576-81.
14. Kieda C, El Hafny-Rahbi B, Collet G, et al. Stable tumor vessel normalization with pO2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment. J Mol Med (Berl) 2013; 91: 883-99.
15. Fylaktakidou KC, Lehn JM, Greferath R, et al. Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin. Bioorg Med Chem Lett 2005; 15: 1605-8.
16. Raykov Z, Balboni G, Aprahamian M, et al. Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer 2004; 109: 742-9.
17. Mutter D, Hajri A, Tassetti V, et al. Increased tumor growth and spread after laparoscopy vs laparotomy: influence of tumor manipulation in a rat model. Surg Endosc 1999; 13: 365-70.
18. Angelova AL, Aprahamian M, Grekova SP, et al. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res 2009; 15: 511-9.
19. Ceyhan GO, Bergmann F, Kadihasanoglu M, et al. Pancreatic neuropathy and neuropathic pain - a comprehensive pathomorphological study of 546 cases. Gastroenterology 2009; 136: 177-86.
20. van Patot MC, Gassmann M,. Hypoxia: adapting to high altitude by mutating EPAS-1, the gene encoding HIF-2alpha. High Alt Med Biol 2011; 12: 157-67.
21. Carmeliet P, Jain RK,. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10: 417-27.
22. Huang G, Chen L,. Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol 2010; 136: 1201-11.
23. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6: 553-63.
24. Masamune A, Kikuta K, Watanabe T, et al. Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2008; 295: G709-17.
25. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
26. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440: 1222-6.
27. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116: 2610-21.
28. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475: 226-30.
29. Yokoi K, Fidler IJ,. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 2004; 10: 2299-306.
30. Fechner G, Dederichs F, Schmidt D, et al. Hyperoxia-induced improvement of the in vitro response to gemcitabine in transitional cell carcinoma. Anticancer Res 2005; 25: 3413-8.
31. Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64: 3731-6.
32. Semenza JC, Suk JE, Estevez V, et al. Mapping climate change vulnerabilities to infectious diseases in Europe. Environ Health Perspect 2012; 120: 385-92.
33. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-7.
34. Bergers G, Hanahan D,. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.